Work

Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.10005

Authors: Suzanne J. Forrest, J. Andrew Livingston, Kieuhoa Tran Vo, Julia Lynne Glade Bender, Amy Opara, Simon Smith, Neel Shah, Nan Chen, Wendy B London, E. Alejandro Sweet-Cordero, Katherine A. Janeway

Institutions: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, The University of Texas MD Anderson Cancer Center, University of California, San Francisco, Memorial Sloan Kettering Cancer Center, AstraZeneca (United Kingdom)

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Osteosarcoma Institute

OpenAlex ID: W4410804843

Cites:

Cited by: 6

Related to: 10